{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:14:15Z","timestamp":1790583255371,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s11095-011-0564-9","type":"journal-article","created":{"date-parts":[[2011,8,23]],"date-time":"2011-08-23T19:48:22Z","timestamp":1314128902000},"page":"411-426","source":"Crossref","is-referenced-by-count":113,"title":["In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug\u2013Drug Interactions"],"prefix":"10.1007","volume":"29","author":[{"given":"Maria","family":"Karlgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Ahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel A. S.","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Palm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Artursson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,23]]},"reference":[{"issue":"8","key":"564_CR1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1124\/dmd.107.014902","volume":"35","author":"C Hilgendorf","year":"2007","unstructured":"Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 2007;35(8):1333\u201340.","journal-title":"Drug Metab Dispos."},{"issue":"52","key":"564_CR2","doi-asserted-by":"crossref","first-page":"37161","DOI":"10.1074\/jbc.274.52.37161","volume":"274","author":"B Hsiang","year":"1999","unstructured":"Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999;274(52):37161\u20138.","journal-title":"J Biol Chem."},{"issue":"3","key":"564_CR3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215\u201336.","journal-title":"Nat Rev Drug Discov."},{"issue":"13","key":"564_CR4","doi-asserted-by":"crossref","first-page":"9626","DOI":"10.1074\/jbc.M004968200","volume":"276","author":"Y Cui","year":"2001","unstructured":"Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001;276(13):9626\u201330.","journal-title":"J Biol Chem"},{"issue":"1","key":"564_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.102.043026","volume":"304","author":"RG Tirona","year":"2003","unstructured":"Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003;304(1):223\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"564_CR6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clpt.2005.07.005","volume":"78","author":"LI Kajosaari","year":"2005","unstructured":"Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005;78(4):388\u201399.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"564_CR7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565\u201381.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"564_CR8","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","volume":"35","author":"A Treiber","year":"2007","unstructured":"Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007;35(8):1400\u20137.","journal-title":"Drug Metab Dispos."},{"issue":"3","key":"564_CR9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2133\/dmpk.19.171","volume":"19","author":"T Mikkaichi","year":"2004","unstructured":"Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet. 2004;19(3):171\u20139.","journal-title":"Drug Metab Pharmacokinet."},{"issue":"6","key":"564_CR10","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1194\/jlr.M500532-JLR200","volume":"47","author":"H Yamaguchi","year":"2006","unstructured":"Yamaguchi H, Okada M, Akitaya S, Ohara H, Mikkaichi T, Ishikawa H, et al. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006;47(6):1196\u2013202.","journal-title":"J Lipid Res."},{"issue":"1","key":"564_CR11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1124\/jpet.106.103390","volume":"318","author":"L Liu","year":"2006","unstructured":"Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, et al. Vectorial transport of enalapril by Oatp1a1\/Mrp2 and OATP1B1 and OATP1B3\/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006;318(1):395\u2013402.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"564_CR12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/17425250902911463","volume":"5","author":"J Kindla","year":"2009","unstructured":"Kindla J, Fromm MF, Konig J. In vitro evidence for the role of OATP and OCT uptake transporters in drug\u2013drug interactions. Expert Opin Drug Metab Toxicol. 2009;5(5):489\u2013500.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"4","key":"564_CR13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1124\/dmd.107.017814","volume":"36","author":"S Matsushima","year":"2008","unstructured":"Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2008;36(4):663\u20139.","journal-title":"Drug Metab Dispos."},{"issue":"2","key":"564_CR14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","volume":"76","author":"SG Simonson","year":"2004","unstructured":"Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76(2):167\u201377.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"564_CR15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.clpt.6100075","volume":"81","author":"PL Giersbergen van","year":"2007","unstructured":"van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther. 2007;81(3):414\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"564_CR16","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1124\/dmd.110.037622","volume":"39","author":"J Kindla","year":"2011","unstructured":"Kindla J, Muller F, Mieth M, Fromm MF, Konig J. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP)1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011;39(6):1047\u201353.","journal-title":"Drug Metab Dispos."},{"issue":"1","key":"564_CR17","first-page":"74","volume":"10","author":"A Poirier","year":"2007","unstructured":"Poirier A, Funk C, Lave T, Noe J. New strategies to address drug\u2013drug interactions involving OATPs. Curr Opin Drug Discov Dev. 2007;10(1):74\u201383.","journal-title":"Curr Opin Drug Discov Dev."},{"issue":"19","key":"564_CR18","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1021\/jm8003152","volume":"51","author":"G Ahlin","year":"2008","unstructured":"Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008;51(19):5932\u201342.","journal-title":"J Med Chem."},{"issue":"1","key":"564_CR19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1124\/jpet.107.124768","volume":"323","author":"P Matsson","year":"2007","unstructured":"Matsson P, Englund G, Ahlin G, Bergstrom CA, Norinder U, Artursson P. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther. 2007;323(1):19\u201330.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"564_CR20","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s11095-009-9896-0","volume":"26","author":"P Matsson","year":"2009","unstructured":"Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res. 2009;26(8):1816\u201331.","journal-title":"Pharm Res"},{"issue":"11","key":"564_CR21","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1021\/jm7015683","volume":"51","author":"JM Pedersen","year":"2008","unstructured":"Pedersen JM, Matsson P, Bergstrom CA, Norinder U, Hoogstraate J, Artursson P. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem. 2008;51(11):3275\u201387.","journal-title":"J Med Chem."},{"issue":"7","key":"564_CR22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","volume":"34","author":"M Hirano","year":"2006","unstructured":"Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug\u2013drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34(7):1229\u201336.","journal-title":"Drug Metab Dispos."},{"key":"564_CR23","unstructured":"Dollery CT, editor. Therapeutic drugs. 2. ed. Edinburgh: Churchill Livingstone; 1999."},{"key":"564_CR24","unstructured":"Goodman LS, Gilman A, Brunton LL, editors. Goodman & Gilman's the pharmacological basis of therapeutics [Electronic resource]. New York: McGraw-Hill; 2005."},{"issue":"12","key":"564_CR25","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1592\/phco.24.17.1732.52347","volume":"24","author":"AJ Busti","year":"2004","unstructured":"Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004;24(12):1732\u201347.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"564_CR26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1034\/j.1600-6143.2001.10415.x","volume":"1","author":"A Asberg","year":"2001","unstructured":"Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant. 2001;1(4):382\u20136.","journal-title":"Am J Transplant"},{"issue":"5","key":"564_CR27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/QAI.0b013e318160a542","volume":"47","author":"JJ Kiser","year":"2008","unstructured":"Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug\/Drug interaction between lopinavir\/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47(5):570\u20138.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"11","key":"564_CR28","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1128\/AAC.01243-06","volume":"51","author":"MJ Lee van der","year":"2007","unstructured":"van der Lee MJ, Blenke AA, Rongen GA, Verwey-van Wissen CP, Koopmans PP, Pharo C, et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother. 2007;51(11):4098\u2013104.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"564_CR29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","volume":"316","author":"RS Obach","year":"2006","unstructured":"Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug\u2013drug interactions. J Pharmacol Exp Ther. 2006;316(1):336\u201348.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"564_CR30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1021\/jm030267j","volume":"47","author":"M Vieth","year":"2004","unstructured":"Vieth M, Siegel MG, Higgs RE, Watson IA, Robertson DH, Savin KA, et al. Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem. 2004;47(1):224\u201332.","journal-title":"J Med Chem."},{"issue":"24","key":"564_CR31","doi-asserted-by":"crossref","first-page":"17159","DOI":"10.1074\/jbc.274.24.17159","volume":"274","author":"T Abe","year":"1999","unstructured":"Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999;274(24):17159\u201363.","journal-title":"J Biol Chem"},{"issue":"5","key":"564_CR32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00210-003-0814-4","volume":"368","author":"T Fehrenbach","year":"2003","unstructured":"Fehrenbach T, Cui Y, Faulstich H, Keppler D. Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003;368(5):415\u201320.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"issue":"1","key":"564_CR33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/bbrc.2000.2922","volume":"273","author":"I Tamai","year":"2000","unstructured":"Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273(1):251\u201360.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"564_CR34","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/db07-1515","volume":"57","author":"I Bachmakov","year":"2008","unstructured":"Bachmakov I, Glaeser H, Fromm MF, Konig J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008;57(6):1463\u20139.","journal-title":"Diabetes"},{"issue":"11","key":"564_CR35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/FPC.0b013e32830d733e","volume":"18","author":"A Kalliokoski","year":"2008","unstructured":"Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics. 2008;18(11):937\u201342.","journal-title":"Pharmacogenet Genomics."},{"issue":"2","key":"564_CR36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1351\/pac198855020199","volume":"55","author":"AT Balaban","year":"1983","unstructured":"Balaban AT. Topological indices based on topological distances in molecular graphs. Pure & Appl Chem. 1983;55(2):199\u2013206.","journal-title":"Pure & Appl Chem."},{"issue":"3","key":"564_CR37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693\u2013705.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"564_CR38","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1128\/AAC.00449-09","volume":"53","author":"PA Pham","year":"2009","unstructured":"Pham PA, la Porte CJ, Lee LS, van Heeswijk R, Sabo JP, Elgadi MM, et al. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother. 2009;53(10):4385\u201392.","journal-title":"Antimicrob Agents Chemother."},{"issue":"13","key":"564_CR39","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1021\/jm2001629","volume":"54","author":"Y Kido","year":"2011","unstructured":"Kido Y, Matsson P, Giacomini KM. Profiling of a prescription drug library for potential renal drug\u2013drug interactions mediated by the organic cation transporter 2. J Med Chem. 2011;54(13):4548\u201358.","journal-title":"J Med Chem."},{"issue":"2","key":"564_CR40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/jpet.104.082370","volume":"314","author":"C Chang","year":"2005","unstructured":"Chang C, Pang KS, Swaan PW, Ekins S. Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther. 2005;314(2):533\u201341.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"564_CR41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11095-006-9159-2","volume":"24","author":"KT Kivisto","year":"2007","unstructured":"Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res. 2007;24(2):239\u201347.","journal-title":"Pharm Res"},{"issue":"8","key":"564_CR42","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1124\/dmd.106.012930","volume":"35","author":"J Noe","year":"2007","unstructured":"Noe J, Portmann R, Brun ME, Funk C. Substrate-dependent drug\u2013drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007;35(8):1308\u201314.","journal-title":"Drug Metab Dispos."},{"issue":"6","key":"564_CR43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FJC.0b013e31817b5b5a","volume":"51","author":"AJ Busti","year":"2008","unstructured":"Busti AJ, Bain AM, Hall 2nd RG, Bedimo RG, Leff RD, Meek C, et al. Effects of atazanavir\/ritonavir or fosamprenavir\/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008;51(6):605\u201310.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"564_CR44","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2000-9426","volume":"20","author":"GA Kullak-Ublick","year":"2000","unstructured":"Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ. Hepatic transport of bile salts. Semin Liver Dis. 2000;20(3):273\u201392.","journal-title":"Semin Liver Dis."},{"issue":"18","key":"564_CR45","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.lfs.2005.12.010","volume":"78","author":"D Pal","year":"2006","unstructured":"Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 2006;78(18):2131\u201345.","journal-title":"Life Sci."},{"issue":"2","key":"564_CR46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clpt.2005.04.007","volume":"78","author":"JT Backman","year":"2005","unstructured":"Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78(2):154\u201367.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"564_CR47","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","volume":"130","author":"RH Ho","year":"2006","unstructured":"Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130(6):1793\u2013806.","journal-title":"Gastroenterology"},{"issue":"6","key":"564_CR48","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clpt.2006.09.010","volume":"80","author":"M Grube","year":"2006","unstructured":"Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006;80(6):607\u201320.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"564_CR49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","volume":"15","author":"Y Kameyama","year":"2005","unstructured":"Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15(7):513\u201322.","journal-title":"Pharmacogenet Genomics."},{"issue":"1\u20133","key":"564_CR50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","volume":"46","author":"P Artursson","year":"2001","unstructured":"Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. 2001;46(1\u20133):27\u201343.","journal-title":"Adv Drug Deliv Rev."},{"issue":"2","key":"564_CR51","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0149-2918(03)80089-9","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 2003;25(2):459\u201371.","journal-title":"Clin Ther"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11095-011-0564-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T05:05:51Z","timestamp":1497935151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-011-0564-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,23]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1007\/s11095-011-0564-9","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,23]]}}}